{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:18:56Z","timestamp":1790255936393,"version":"4.1.0"},"reference-count":24,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,7,31]]},"DOI":"10.2217\/fon.15.47","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T10:03:43Z","timestamp":1437559423000},"page":"2043-2048","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":43,"title":["Crizotinib-Induced Cardiotoxicity: The Importance of a Proactive Monitoring and Management"],"prefix":"10.1080","volume":"11","author":[{"given":"Alfredo","family":"Tartarone","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028Rionero in Vulture(PZ), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Gallucci","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Onco-Hematology IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture(PZ), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lazzari","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Toracica Istituto Europeo di Oncologia Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lerose","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Department of Onco-Hematology IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture(PZ), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028Rionero in Vulture(PZ), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, via Padre Pio 1, 85028Rionero in Vulture(PZ), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,7,22]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0078-5"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu199"},{"key":"e_1_3_2_9_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non Small Cell Lung Cancer Version I. 2015. www.nccn.org."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1740"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000375"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.776831"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2008.00090.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.206920"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3252"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq378"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.04.027"},{"key":"e_1_3_2_18_1","first-page":"353","article-title":"An analysis of time relations of electrocardiograms","volume":"7","author":"Bazet JC","year":"1920","unstructured":"Bazet JC . An analysis of time relations of electrocardiograms. Heart7, 353\u2013367 (1920).","journal-title":"Heart"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1921.tb15167.x"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2010.05.005"},{"key":"e_1_3_2_21_1","first-page":"4733","article-title":"Liposomes ameliorate crizotinib and nilotinib-induced inhibition of the cardiac channel IKR and QTc prolongation","volume":"34","author":"Shopp GM","year":"2014","unstructured":"Shopp GM , HelsonL, BouchardAet al. Liposomes ameliorate crizotinib and nilotinib-induced inhibition of the cardiac channel IKR and QTc prolongation. Anticancer Res.34, 4733\u20134740 (2014).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_22_1","unstructured":"Xalkori (Pfizer Inc.) prescribing information [package insert]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202570s000lbl.pdf."},{"issue":"8","key":"e_1_3_2_23_1","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of theconcentration-QTc relationship of crizotinib (PF-02341066), an anaplasticlymphoma kinase and c-MET\/hepatocyte growth factor receptor dual inhibitoradministered orally to patients with advanced cancer","volume":"70","author":"Nickens D","year":"2010","unstructured":"Nickens D , TanW, WilnerKet al. Pharmacokinetic\/pharmacodynamic evaluation of theconcentration-QTc relationship of crizotinib (PF-02341066), an anaplasticlymphoma kinase and c-MET\/hepatocyte growth factor receptor dual inhibitoradministered orally to patients with advanced cancer. Cancer Res.70(Suppl. 8), Abstract 1673 (2010).","journal-title":"Cancer Res."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28040"},{"key":"e_1_3_2_25_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u20132006\u201314_QuickReference_5x7.pdf."},{"key":"e_1_3_2_26_1","unstructured":"Summary Basis of Decision (SBD): Xalkori -2012- Health Canada Paragraph 3.3.1 Pharmacodynamics. www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2012_xalkori_145155-eng.php."}],"updated-by":[{"DOI":"10.2217\/fon.15.201","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T00:00:00Z","timestamp":1438819200000}}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.47","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:22Z","timestamp":1719124942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,22]]},"references-count":24,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,7,31]]}},"alternative-id":["10.2217\/fon.15.47"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.47","relation":{"correction":[{"id-type":"doi","id":"10.2217\/fon.15.201","asserted-by":"object"}]},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}